Abstract: A compound represented by formula (I), or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotope marker, isomer or prodrug thereof. Also provided are a pharmaceutical composition comprising the same, and the use of the compound and the pharmaceutical composition in the preparation of a medicament for treating tyrosine kinase-mediated diseases. The provided compound and the pharmaceutical composition thereof have significant tyrosine kinase inhibitory activity, can overcome tumor drug resistance, can break through the blood-brain barrier, and further have excellent pharmacokinetic properties and excellent oral bioavailability, and can be administered in a small dose, thereby reducing treatment cost for patients and possible side effects; therefore, the provided compound and the pharmaceutical composition thereof have great application potentials.

Abstract: Positive reference spiked in collected sample for use in qualitatively and quantitatively detecting viral RNA.

Abstract: The present invention provides an aripiprazole sustained-release microsphere and a preparation method therefor. The microsphere comprises aripiprazole and polylactide-glycolide. The microsphere is of a spherical reticular skeleton structure, with reticular micropores distributed in the spherical surface, and aripiprazole filled in the micropores. The average particle diameter of the microsphere is less than 20 ?m, and is suitable for a 5 gauge needle. The content of aripiprazole is 65%-80% of the total weight of the microsphere.

Abstract: An array substrate is provided. The array substrate includes a substrate, a light-shielding layer, and an active layer. The light-shielding layer is disposed on the substrate, and the active layer is disposed on the light-shielding layer. Wherein, an orthographic projection of the active layer on the substrate is positioned within an orthographic projection of the light-shielding layer on the substrate. The present disclosure prevents the active layer from forming ramps and then breaking by allowing the orthographic projection of the active layer on the substrate to be positioned within the orthographic projection of the light-shielding layer on the substrate, thereby ensuring performances of the array substrate.

Abstract: Provided are an amino acid dehydrogenase mutant and use thereof. The amino acid sequence of the amino acid dehydrogenase mutant has a sequence as shown in SEQ ID NO: 1, and sites at which amino acid mutations occur include a K144G site.

Abstract: A method for determining a quantity of passive inter-modulation sources. A quantity of passive inter-modulation sources of a multi-antenna device is obtained. An interference signal that is excited by a sounding signal and that is from a passive inter-modulation source is received. Singular value decomposition is performed on a first matrix corresponding to the interference signal. A quantity of passive inter-modulation sources is determined based on a result of the singular value decomposition. In this way, the quantity of passive inter-modulation sources of the multi-antenna device is directly determined by performing operations including signal receiving and sending and calculation of the multi-antenna device, to implement convenient, accurate, and secure detection of information about the quantity of the passive inter-modulation sources of the multi-antenna device.

Abstract: A deep learning-based method for calculating an overhang of a battery includes the following steps: obtaining a training sample image set; training a neural network according to the training sample image set to obtain a segmentation network model; detecting an object detection image of the battery to be detected according to the segmentation network model to obtain a corresponding first binarized image; obtaining top coordinates of each of a positive electrode and a negative electrode of the battery to be detected according to the first binarized image; and calculating the overhang of the battery to be detected according to the top coordinates.

Abstract: Pyrazolopyrazine derived compounds as represented by general formulas (AI) and (I) or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an isotopic marker or an isomer thereof. Provided are a pharmaceutical composition comprising same and use of the compounds and the pharmaceutical composition in the preparation of medicaments for treating JAK kinase-mediated diseases. The compounds and pharmaceutical composition thereof provided have significant JAK kinase inhibitory activity, and in particular, have relatively high Tyk2 kinase inhibitory activity and selectivity for JAK2, and therefore have a very promising application potential.

Abstract: A deep learning-based method for calculating an overhang of a battery includes the following steps: obtaining a training sample image set; training a neural network according to the training sample image set to obtain a segmentation network model; detecting an object detection image of the battery to be detected according to the segmentation network model to obtain a corresponding first binarized image; obtaining top coordinates of each of a positive electrode and a negative electrode of the battery to be detected according to the first binarized image; and calculating the overhang of the battery to be detected according to the top coordinates.

Abstract: The present invention provides a compound as represented by formula (1) or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an isotope label, an isomer or a prodrug thereof. The present invention also provides a pharmaceutical composition containing the same and the use of the compound and the pharmaceutical composition in preparation of drugs for treating tyrosine kinase-mediated diseases. The compound and the pharmaceutical composition comprising same provided by the present disclosure have significant tyrosine kinase inhibitory activity, can overcome tumor drug resistance, and break through through blood-brain barrier, also have excellent pharmacokinetic properties and excellent oral bioavailability, and can be administered in a small dosage, thereby reducing treatment costs of and possible side effects to a patient. Thus, the application potential is very great.

Abstract: Provided is a quinolyl-containing compound as shown in general formula (I) or (II) or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an isotopic label, or an isomer thereof, and further provided are a pharmaceutical composition comprising the compound and use of the compound and the pharmaceutical composition. The provided compound has a dual molecule function, can serve as multi-target inhibitors of novel tyrosine kinase/histone deacetylase, can simultaneously achieve the effect of two inhibitors, has excellent biological activity and pharmacokinetic properties, and has the application potential particularly in the field of treatment of tumors.

Abstract: Disclosed are a somatosensory remote controller, a somatosensory remote control flight system and method, and a remote control method. The somatosensory remote controller comprises: a motion sensor, a controller, a first transmission module, and a remote controller body. The motion sensor, the first transmission module, and the controller are all disposed on the remote controller body, and the motion sensor and the first transmission module are electrically connected to the controller. The motion sensor acquires initial state information of a current position of the remote controller body and movement information about movement of the remote controller body, and transmit the same to the controller. The controller is configured to receive, according to the initial state information and the movement information, a flight instruction, and send the flight instruction via the first transmission module.

Abstract: The present disclosure proposes an intelligent device that comprises a body comprising a controller and a first interface; the controller is in connection with the first interface; the body of the intelligent device is connected with an external device via the first interface; different external devices are connected with the body of the intelligent device to form various intelligent devices so as to meet the use requirements in different scenes.

Abstract: A control system is disclosed. The control system comprises a controlling terminal and a controlled device; the controlling terminal comprises a height measuring device and a processing unit; the height measuring device is configured to measure and obtain a height information of the controlling terminal, and send the height information to the processing unit; the processing unit is configured to receive the height information and generate an operation command; the controlled device is configured to receive the operation command and perform a corresponding motion according to the operation command.

Abstract: An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer.

Abstract: Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.

Abstract: The present application relates to a macrocycle containing aminopyrazole and pyrimidine, which is represented by formula (I), a pharmaceutical composition thereof, and a use thereof in inhibiting tropomyosin receptor kinase (Trk) activity and in treating diseases in mammals that are mediated by Trk.

Abstract: An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer.

Abstract: Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.

Abstract: Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.